AbbVie Celebrates Launch as New Biopharmaceutical Company with Employees, Patients

AbbVie Celebrates Launch as New Biopharmaceutical Company with Employees, Patients PR Newswire NEW YORK, Jan. 2, 2013 NEW YORK, Jan. 2, 2013 /PRNewswire/ -- AbbVie (NYSE:ABBV) today marks its launch as an independent biopharmaceutical company, with employees from more than 40 countries and patients joining AbbVie leaders as they ring the first opening bell of 2013 at the New York Stock Exchange. To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/59757-abbvie-celebrates-launch-as-new- biopharmaceutical-company With a rich, 125-year heritage of developing pharmaceuticals, AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. A global enterprise that serves patients in more than 170 countries, AbbVie launches with an estimated $18 billion in annual revenues and a strong commitment to creating shareholder value through long-term growth potential and the continuation of the company's history of shareholder dividends. "Today AbbVie launches with an outstanding portfolio, a solid pipeline and enthusiastic people who will serve patients and deliver growth," said Richard A. Gonzalez, Chairman of the Board and Chief Executive Officer, AbbVie. "With those assets and a relentless focus on innovation we intend to create significant value for our shareholders.